Empirico's unique internal capabilities in human genetics and siRNA medicines, augmented by those of our partners, are driving the advancement of a growing and differentiated pipeline of wholly-owned and partnered programs. Our wholly-owned lead siRNA program is expected to enter clinical trials in 2024.